1
|
Kandhasamy K, Surajambika RR, Velayudham PK. Pyrazolo - Pyrimidines as Targeted Anticancer Scaffolds - A Comprehensive Review. Med Chem 2024; 20:293-310. [PMID: 37885114 DOI: 10.2174/0115734064251256231018104623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 09/08/2023] [Accepted: 09/15/2023] [Indexed: 10/28/2023]
Abstract
BACKGROUND Globally, cancer is the leading cause of death, which causes 10 million deaths yearly. Clinically, several drugs are used in treatment but due to drug resistance and multidrug resistance, there occurs a failure in the cancer treatment. OBJECTIVES The present review article is a comprehensive review of pyrazole and pyrimidine hybrids as potential anticancer agents. METHODS The review comprises more than 60 research works done in this field. The efficiency of the reported pyrazolopyrimidine fused heterocyclic with their biological data and the influence of the structural aspects of the molecule have been discussed. RESULTS This review highlighted pyrazolo-pyrimidines as targeted anticancer agents with effect on multiple targets. CONCLUSION The review will be helpful for the researchers involved in targeted drugs for cancer therapy for designing new scaffolds with pyrazolo-pyrimidine moieties.
Collapse
Affiliation(s)
- Kesavamoorthy Kandhasamy
- Department of Pharmaceutical Chemistry, C.L. Baid Metha College of Pharmacy, Chennai- 600 097, India
| | | | - Pradeep Kumar Velayudham
- Department of Pharmaceutical Chemistry, C.L. Baid Metha College of Pharmacy, Chennai- 600 097, India
| |
Collapse
|
2
|
Bennani FE, Doudach L, Karrouchi K, Tarib A, Rudd CE, Ansar M, Faouzi MEA. Targeting EGFR, RSK1, RAF1, PARP2 and LIN28B for several cancer type therapies with newly synthesized pyrazole derivatives via a computational study. J Biomol Struct Dyn 2023; 41:4194-4218. [PMID: 35442150 DOI: 10.1080/07391102.2022.2064915] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Accepted: 04/06/2022] [Indexed: 10/18/2022]
Abstract
Cancer remains the leading cause of death in the world despite the significant advancements made in anticancer drug discovery. This study is aimed to computationally evaluate the efficacy of 63 in-house synthesized pyrazole derivatives targeted to bind with prominent cancer targets namely EGFR, RSK1, RAF1, PARP2 and LIN28B known to be expressed, respectively, in lung, colon, skin, ovarian and pancreatic cancer cells. Initially, we perform the molecular docking investigations for all pyrazole compounds with a comparison to known standard drugs for each target. Docking studies have revealed that some pyrazole compounds possess better binding affinity scores than standard drug compounds. Thereafter, a long-range of 1 μs molecular dynamic (MD) simulation study for top ranked docked compounds with all respective proteins was carried out to assess the interaction stability in a dynamic environment. The results suggested that the top ranked complexes showed a stable interaction profile for a longer period of time. The outcome of this study suggests that pyrazole compounds, M33, M36, M76 and M77, are promising molecular candidates that can modulate the studied target proteins significantly in comparison to their known inhibitor based on their selective binding interactions profile. Furthermore, ADME-T profile has been explored to check for the drug-likeness and pharmacokinetics profiles and found that all proposed compounds exhibited acceptable values for being a potential drug-like candidate with non-toxic characteristics. Overall, extensive computational investigations indicate that the four proposed pyrazole inhibitors/modulators studied against each respective target protein will be helpful for future cancer therapeutic developments.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Fatima Ezzahra Bennani
- Laboratory of Pharmacology and Toxicology, Bio Pharmaceutical and Toxicological Analysis Research Team, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
- Laboratory of Analytical Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
- Division of Immunology-Oncology, Centre de Recherche Hôpital Maisonneuve-Rosemont (CR-HMR), Montreal, QC, Canada
- Laboratory of Medicinal Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
| | - Latifa Doudach
- Department of Biomedical Engineering Medical Physiology, Higher School of Technical Education of Rabat, Mohammed V University in Rabat, Rabat, Morocco
| | - Khalid Karrouchi
- Laboratory of Analytical Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
| | - Abdelilah Tarib
- Laboratory of Pharmacology and Toxicology, Bio Pharmaceutical and Toxicological Analysis Research Team, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
| | - Christopher E Rudd
- Division of Immunology-Oncology, Centre de Recherche Hôpital Maisonneuve-Rosemont (CR-HMR), Montreal, QC, Canada
- Department of Microbiology, Infection and Immunology, Faculty of Medicine, Université de Montreal, Montreal, QC, Canada
- Division of Experimental Medicine, Department of Medicine, McGill University Health Center, McGill University, Montreal, QC, Canada
| | - M'hammed Ansar
- Laboratory of Medicinal Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
| | - My El Abbes Faouzi
- Laboratory of Pharmacology and Toxicology, Bio Pharmaceutical and Toxicological Analysis Research Team, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
| |
Collapse
|
3
|
Ruzi Z, Bozorov K, Nie L, Zhao J, Akber Aisa H. Discovery of novel (E)-1-methyl-9-(3-methylbenzylidene)-6,7,8,9-tetrahydropyrazolo[3,4-d]pyrido[1,2-a]pyrimidin-4(1H)-one as DDR2 kinase inhibitor: Synthesis, molecular docking, and anticancer properties. Bioorg Chem 2023; 135:106506. [PMID: 37030105 DOI: 10.1016/j.bioorg.2023.106506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2022] [Revised: 03/26/2023] [Accepted: 03/28/2023] [Indexed: 04/05/2023]
Abstract
We report the synthesis, molecular docking and anticancer properties of the novel compound (E)-1-methyl-9-(3-methylbenzylidene)-6,7,8,9-tetrahydropyrazolo[3,4-d]pyrido[1,2-a]pyrimidin-4(1H)-one (PP562). PP562 was screened against sixteen human cancer cell lines and exhibited excellent antiproliferative activity with IC50 values ranging from 0.016 to 5.667 μM. Experiments were carried out using the target PP562 at a single dose of 1.0 μM against a kinase panel comprising 100 different enzymes. A plausible binding mechanism for PP562 inhibition of DDR2 was determined using molecular dynamic analysis. The effect of PP562 on cell proliferation was also examined in cancer cell models with both high and low expression of the DDR2 gene; PP562 inhibition of high-expressing cells was more prominent than that for low expressing cells. PP562 also exhibits excellent anticancer potency toward the HGC-27 gastric cancer cell line. In addition, PP562 inhibits colony formation, cell migration, and adhesion, induces cell cycle arrest at the G2/M phase, and affects ROS generation and cell apoptosis. After DDR2 gene knockdown, the antitumor effects of PP562 on tumor cells were significantly impaired. These results suggested that PP562 might exert its inhibitory effect on HCG-27 proliferation through the DDR2 target.
Collapse
|
4
|
James JP, Devaraji V, Sasidharan P, T. S. P. Pharmacophore Modeling, 3D QSAR, Molecular Dynamics Studies and Virtual Screening on Pyrazolopyrimidines as anti-Breast Cancer Agents. Polycycl Aromat Compd 2022. [DOI: 10.1080/10406638.2022.2135545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Jainey P. James
- Department of Pharmaceutical Chemistry, Nitte (Deemed to Be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Deralakatte, India
| | - Vinod Devaraji
- Computational Drug Design Lab, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India
| | - Pradija Sasidharan
- Department of Pharmaceutical Chemistry, Nitte (Deemed to Be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Deralakatte, India
| | - Pavan T. S.
- Department of Pharmaceutical Chemistry, Nitte (Deemed to Be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Deralakatte, India
| |
Collapse
|
5
|
Farag PS, AboulMagd AM, Hemdan MM, Hassaballah AI. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study. Bioorg Chem 2022; 130:106231. [DOI: 10.1016/j.bioorg.2022.106231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 10/08/2022] [Accepted: 10/26/2022] [Indexed: 11/15/2022]
|
6
|
Li W, Zhang J, Wang M, Dong R, Zhou X, Zheng X, Sun L. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery. Curr Top Med Chem 2022; 22:284-304. [PMID: 35021973 DOI: 10.2174/1568026622666220111143949] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 12/30/2021] [Accepted: 12/30/2021] [Indexed: 11/22/2022]
Abstract
Pyrimidine-fused derivatives that are the inextricable part of DNA and RNA play a key role in the normal life cycle of cells. Pyrimidine-fused dinitrogenous penta-heterocycles including pyrazolopyrimidines and imidazopyrimidines is a special class of pyrimidine-fused compounds contributing to an important portion in anti-cancer drug discovery, which have been discovered as core structure for promising anti-cancer agents used in clinic or clinical evaluations. Pyrimidine-fused dinitrogenous penta-heterocycles have become one privileged scaffold for anti-cancer drug discovery. This review consists of the recent progress of pyrimidine-fused dinitrogenous penta-heterocycles as anti-cancer agents and their synthetic strategies. In addition, this review also summarizes some key structure-activity relationships (SARs) of pyrimidine-fused dinitrogenous penta-heterocycle derivatives as anti-cancer agents.
Collapse
Affiliation(s)
- Wen Li
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Jinyang Zhang
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Min Wang
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Ru Dong
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Xin Zhou
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Xin Zheng
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| | - Liping Sun
- Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, PR China
| |
Collapse
|
7
|
Farghaly TA, Dawood KM. Inhibitory Activities of Pyrazolo-Oxazine Heterocyclic Derivatives. Mini Rev Med Chem 2021; 22:1256-1267. [PMID: 34967287 DOI: 10.2174/1389557522666211229114446] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 07/05/2021] [Accepted: 09/10/2021] [Indexed: 11/22/2022]
Abstract
Despite several reports and reviews addressing the biological significance of pyrazoles and oxazines, no comprehensive work on the pyrazolo oxazine fused ring system has been published so far.We report all biological evaluations on pyrazolo-oxazine derivatives in this mini-review to provide an avenue for medicinal and pharmacological researchers to conduct further in-depth exploration.
Collapse
Affiliation(s)
- Thoraya A Farghaly
- Department of Chemistry, Faculty of Science, Cairo University, Giza, 12613, Egypt
- Department of Chemistry, Faculty of Applied Science, Umm Al-Qura University, Makkah Almukkarramah, Saudi Arabia
| | - Kamal M Dawood
- Department of Chemistry, Faculty of Science, Cairo University, Giza, 12613, Egypt
| |
Collapse
|
8
|
Abstract
Pyrazolo-oxazine fused systems are interesting classes of heterocyclic compounds
exhibiting pronounced biological applications such as anticancer, antitubercular,
anti-inflammatory, antibacterial and antifungal activities as well as inhibiting COX-1 and
COX-2 enzymes. Depending on the distribution position of the heteroatoms (N and O), there
are fourteen different systems of pyrazolo-oxazine. Nine of them were biologically abundant
in literature, for example, pyrazolo[3,4-e][1,3]oxazines are used as analogs of antibiotics
Formycin, Formycin B, Oxoformycin B. This review article summarizes the concerted efforts
expended on most of the synthetic routes to the various types of pyrazolo-oxazines in
the literature until the first quarter of 2020. The reactions of pyrazolo-oxazines with various
reagents are also outlined.
Collapse
Affiliation(s)
- Kamal M. Dawood
- Department of Chemistry, Faculty of Science, Cairo University, Giza, 12613, Egypt
| | - Thoraya A. Farghaly
- Department of Chemistry, Faculty of Science, Cairo University, Giza, 12613, Egypt
| | - Mohamed A. Raslan
- Department of Chemistry, Faculty of Science, Aswan University, 81528 Aswan, Egypt
| |
Collapse
|
9
|
Rao RN, Chanda K. An assessment study of known pyrazolopyrimidines: Chemical methodology and cellular activity. Bioorg Chem 2020; 99:103801. [PMID: 32278206 DOI: 10.1016/j.bioorg.2020.103801] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 03/22/2020] [Accepted: 03/24/2020] [Indexed: 10/24/2022]
Abstract
Heterocyclic compounds with nitrogen atom play a key role in the normal life cycle of a cell. Pyrazolopyrimidine is a privileged class of nitrogen containing fused heterocyclic compound contributing to a major portion of all lead molecules in medicinal chemistry. The thumbprint of pyrazolopyrimidine as a pharmacophore is always noticeable due to its analogy with the adenine base in DNA. Pyrazolopyrimidines are divided into five types [I, II, III, IV, V] based on the mechanism of action on the specific target conferring a wide scope of research which has accelerated the interest of researchers to investigate its biological profile. In 1956, the anti-cancer activity of pyrazolopyrimidine was evaluated for the first time with appreciable results. Since then, medicinal chemists centered their work on various methods of synthesis and evaluating the biological profile of pyrazolopyrimidine isomers. This report consists of novel methodologies followed to synthesize pyrazolopyrimidine isomers along with a note on their biological significance. To the best of our knowledge, this review article will be first of its kind to encompass different synthetic procedures along with anti-cancer, kinase inhibition, phosphodiesterase inhibition and receptor blocking activity of pyrazolopyrimidine moieties. IC50 values of potent compounds are added wherever necessary to understand the suitability of pyrazolopyrimidine skeletons for a specific biological activity.
Collapse
Affiliation(s)
- R Nishanth Rao
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, India
| | - Kaushik Chanda
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, India
| |
Collapse
|
10
|
Kamal R, Kumar R, Kumar V, Bhardwaj V. Synthetic Utilization of α,β‐Chalcone Dibromide In Heterocyclic Chemistry and Stereoselective Debromination. ChemistrySelect 2019. [DOI: 10.1002/slct.201902262] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Raj Kamal
- Department of ChemistryKurukshetra University Kurukshetra Haryana India- 136119
| | - Ravinder Kumar
- Department of ChemistryKurukshetra University Kurukshetra Haryana India- 136119
| | - Vipan Kumar
- Department of ChemistryKurukshetra University Kurukshetra Haryana India- 136119
| | - Vikas Bhardwaj
- Department of ChemistrySeth Jai Parkash Mukad Lal Institute of Engineering and Technology Radaur. Yamunanagar Haryana 135133 India
| |
Collapse
|
11
|
l-Amino acid oxidase from Cerastes vipera snake venom: Isolation, characterization and biological effects on bacteria and tumor cell lines. Toxicon 2018; 150:270-279. [DOI: 10.1016/j.toxicon.2018.06.064] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2018] [Revised: 05/27/2018] [Accepted: 06/07/2018] [Indexed: 11/22/2022]
|
12
|
Allam M, Bhavani A, Mudiraj A, Ranjan N, Thippana M, Babu PP. Synthesis of pyrazolo[3,4-d]pyrimidin-4(5H)-ones tethered to 1,2,3-triazoles and their evaluation as potential anticancer agents. Eur J Med Chem 2018; 156:43-52. [DOI: 10.1016/j.ejmech.2018.06.055] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 06/23/2018] [Accepted: 06/23/2018] [Indexed: 01/22/2023]
|
13
|
Hamid SBA, Titinchi SJJ, Abbo H, Khaligh NG. One-Pot Multicomponent Synthesis of Pyrazolo[3,4-d]pyrimidine-6-one Derivatives. Polycycl Aromat Compd 2016. [DOI: 10.1080/10406638.2016.1194298] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Sharifah Bee Abd Hamid
- Nanotechnology & Catalysis Research Centre (NANOCAT), University of Malaya, Kuala Lumpur, Malaysia
| | - Salam J. J. Titinchi
- Department of Chemistry, University of the Western Cape, Cape Town, South Africa
| | - Hanna Abbo
- Department of Chemistry, University of the Western Cape, Cape Town, South Africa
| | - Nader Ghaffari Khaligh
- Nanotechnology & Catalysis Research Centre (NANOCAT), University of Malaya, Kuala Lumpur, Malaysia
- Department of Chemistry, University of the Western Cape, Cape Town, South Africa
| |
Collapse
|
14
|
|
15
|
Ismail NS, Ali EM, Ibrahim DA, Serya RA, Abou El Ella DA. Pyrazolo[3,4-d]pyrimidine based scaffold derivatives targeting kinases as anticancer agents. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES 2016. [DOI: 10.1016/j.fjps.2016.02.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
16
|
Liu M, Li J, Chai H, Zhang K, Yang D, Zhang Q, Shi D. A convenient four-component one-pot strategy toward the synthesis of pyrazolo[3,4-d]pyrimidines. Beilstein J Org Chem 2015; 11:2125-31. [PMID: 26664633 PMCID: PMC4660965 DOI: 10.3762/bjoc.11.229] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Accepted: 10/29/2015] [Indexed: 01/23/2023] Open
Abstract
An efficient one-pot synthesis of pyrazolo[3,4-d]pyrimidine derivatives by the four-component condensation of hydrazines, methylenemalononitriles, aldehydes and alcohols has been developed via two different reaction pathways. The structures of target products were characterized by IR spectroscopy, NMR (1H and 13C) spectroscopy and HRMS (ESI) spectrometry. The crystal structure of 4-ethoxy-6-(2-nitrophenyl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine was determined by single crystal X-ray diffraction.
Collapse
Affiliation(s)
- Mingxing Liu
- School of Chemical Engineering and Environment, Beijing Institute of Technology, Beijing, 100081, China
| | - Jiarong Li
- School of Chemical Engineering and Environment, Beijing Institute of Technology, Beijing, 100081, China
| | - Hongxin Chai
- School of Chemical Engineering and Environment, Beijing Institute of Technology, Beijing, 100081, China
| | - Kai Zhang
- School of Chemical Engineering and Environment, Beijing Institute of Technology, Beijing, 100081, China
| | - Deli Yang
- School of Chemical Engineering and Environment, Beijing Institute of Technology, Beijing, 100081, China
| | - Qi Zhang
- School of Chemical Engineering and Environment, Beijing Institute of Technology, Beijing, 100081, China
| | - Daxin Shi
- School of Chemical Engineering and Environment, Beijing Institute of Technology, Beijing, 100081, China
| |
Collapse
|
17
|
Nemati F, Nikkhah SH, Elhampour A. An environmental friendly approach for the catalyst-free synthesis of highly substituted pyrazoles promoted by ultrasonic radiation. CHINESE CHEM LETT 2015. [DOI: 10.1016/j.cclet.2015.07.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|